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There is an increasing interest in the potential of exhaled biomarkers, such as volatile organic compounds (VOCs),
to improve accurate diagnoses and management decisions in pulmonary diseases. The objective of this manuscript
is to systematically review the current knowledge on exhaled VOCs with respect to their potential clinical use in
asthma, lung cancer, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and respiratory tract
infections. A systematic literature search was performed in PubMed, EMBASE, Cochrane database, and reference lists
of retrieved studies. Controlled, clinical, English-language studies exploring the diagnostic and monitoring value of
VOCs in asthma, COPD, CF, lung cancer and respiratory tract infections were included. Data on study design,
setting, participant characteristics, VOCs techniques, and outcome measures were extracted. Seventy-three studies
were included, counting in total 3,952 patients and 2,973 healthy controls. The collection and analysis of exhaled
VOCs is non-invasive and could be easily applied in the broad range of patients, including subjects with severe
disease and children. Various research groups demonstrated that VOCs profiles could accurately distinguish patients
with a pulmonary disease from healthy controls. Pulmonary diseases seem to be characterized by a disease specific
breath-print, as distinct profiles were found in patients with dissimilar diseases. The heterogeneity of studies
challenged the inter-laboratory comparability. In conclusion, profiles of VOCs are potentially able to accurately
diagnose various pulmonary diseases. Despite these promising findings, multiple challenges such as further
standardization and validation of the diverse techniques need to be mastered before VOCs can be applied into
clinical practice.
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Introduction
Background and aim
Pulmonary diseases are important causes of morbidity in
both adults and children [1,2]. The diverse pulmonary
diseases go along with clinical challenges. In adults, lung
cancer is one of the leading causes of death worldwide. It
is often diagnosed at an advanced stage when successful
treatment is difficult [3]. Furthermore, chronic obstructive
pulmonary disease (COPD) and asthma are prevalent lung* Correspondence: kim.vande.kant@mumc.nl
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distribution, and reproduction in any mediumdiseases that account for a major burden on society in
terms of morbidity and health care costs. Early diagnosis
and close monitoring of both diseases are important for
proper treatment decisions, optimal disease control and
prognosis. However, the available clinical tools are not
always fulfilling. In young children, a reliable asthma diag-
nosis is difficult as there are no tools available to discrimin-
ate between true asthmatics and children with transient,
virus-induced symptoms. On account of these clinical chal-
lenges, there is a continuous search for techniques that can
improve accurate diagnoses and management decisions. A
potential non-invasive technique is the analysis of volatile
biomarkers in exhaled breath, so called volatile organic
compounds (VOCs). In this manuscript we systematicallyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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potential clinical use in pulmonary diseases.
The origin of exhaled volatile organic compounds
Asthma, COPD, Cystic Fibrosis (CF), and lung cancer
are characterized by inflammation and oxidative stress.
Monitoring of airway inflammation and oxidative stress
can be helpful in the diagnosis and monitoring of these
diseases. Current available techniques to directly measure
inflammation and oxidative stress in the airways are
bronchoscopy, bronchoalveolar lavage and biopsy. These
techniques are too invasive for repeated routine use,
especially in children. The need for non-invasive analysis of
inflammation and oxidative stress in the lungs has led to
increasing interest in exhaled breath analysis (Figure 1).
Fractional exhaled Nitric Oxide (FeNO) is the most exten-
sively studied marker in exhaled breath. Although the
analysis of FeNO might be a helpful clinical tool in some
pulmonary diseases, it has several limitations. For example
in asthma, FeNO is especially a marker of allergic inflam-
mation and therefore of limited use in non-allergic patients
[4]. Consequently, additional exhaled biomarkers were
studied. Next to non-volatile biomarkers that can be
assessed in exhaled breath condensate, the analysis of
exhaled VOCs gained popularity. VOCs are a diverse
group of carbon-based chemicals that are volatile at
room temperature. The source of exhaled VOCs can be
exogenous or endogenous. Some VOCs can be taken up
as pollutants from the environment via the skin or by
inhalation or ingestion. Subsequently, these compounds
are metabolized and exhaled. Other VOCs are formed in
the body during several (patho)physiological processes
[5,6]. An important group of endogenously formed VOCsFigure 1 Techniques to assess airway inflammation and oxidative stre
oxidative stress ranging from completely non-invasive (exhaled breath anaare hydrocarbons that are formed by lipid peroxidation.
During the inflammatory process, Reactive Oxygen Species
(ROS) are produced by inflammatory cells. Subsequently,
ROS react with lipid membrane structures and cause
degradation of polyunsaturated fatty acids. As a result
several stable breakdown products including hydrocarbons
are formed [5,6]. Besides hydrocarbons, other VOCs can be
identified, including nitrogen, oxygen or sulphur containing
compounds. These VOCs can be formed by bacteria or
during (patho)physiological processes in the liver, kidneys,
and pancreas [5,6]. As soon as VOCs are formed, they are
either further oxidized into smaller components due to
enhanced activity of enzymes (such as cytochrome P450
oxidase), or they directly enter the bloodstream [7].
Subsequently, VOCs are excreted into breath. Early
findings of distinct VOCs in diseased people (e.g. with
diabetes or cirrhosis) compared to healthy controls stimu-
lated investigators to elucidate the clinical potential of
exhaled VOCs in pulmonary diseases [5]. Since exhaled
VOCs are formed during inflammatory processes, the ana-
lysis of VOCs may be a promising non-invasive technique
to directly monitor inflammation and oxidative stress in the
airways. This information might be of help in the diagnosis
and monitoring of pulmonary diseases.
Technical analysis of exhaled breath
There are multiple techniques described to collect, detect,
and analyze exhaled VOCs [6,8,9]. The most commonly
used techniques are gas chromatography (GC), which is the
gold standard, and the electronic nose (eNose). With the
GC-technique, exhaled breath is firstly collected and
temporarily stored (e.g. in inert bags or sorption tubes).







trans bronchial lung biopsy
open lung biopsy
ss. There are various methods to measure airway inflammation and
lysis) to very invasive (open lung biopsy).
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flame ionization detection (GC-FID) [6]. The diverse VOCs
are first separated based on their chemical properties
and consecutively ionized and separated by their mass-
to-charge (m/z) ratio (Figure 2). Breath samples can also
be analyzed using an eNose [9]. The eNose consists of
an array of nanosensors. When these sensors are
exposed to a mixture of VOCs, a change in their electrical
resistance is induced, leading to the production of a
‘breath-print’ (Figure 3). This breath-print represents the
complex mixture of exhaled VOCs and can be used for
pattern-recognition algorithms in multiple diseases [10-13].
A limitation of the eNose is that it is unable to analyze indi-
vidual VOCs. In addition to GC and the eNose, other tech-
niques that are used to study VOCs in pulmonary diseases
include; proton transfer reaction mass spectrometry
(PTR-MS), selected ion flow tube mass spectrometry
(SIFT-MS), ion mobility spectrometry (IMS), laser spec-
troscopy, colorimetric sensor array, and gold nano particles
sensors (GNPs).Figure 2 Breath-print of VOCs by gas chromatography. With the gas c
temporarily stored in e.g. gas-tight syringes, glass bulbs, inert bags, or meta
they can be released for analysis. This is often performed by solvent or the
components can be assessed by GC usually followed by mass spectrometr
separated and quantified by using their specific compound characteristics.
the GC column at different time points; the retention time. Based on their
figure demonstrates an example of a chromatogram of a breath sample an
while the y axis shows the relative abundance of various compound signalMaterials and methods
Data sources and search criteria
A systematic literature search was performed until July
2012 in PubMed, EMBASE, and the Cochrane Central
Register of Controlled trials. Keywords/Mesh terms in-
cluded: asthma, chronic obstructive pulmonary disease,
COPD, cystic fibrosis, lung cancer, pulmonary disease,
respiratory infection, combined with: volatile organic com-
pounds, VOC, VOCs, exhaled breath or electronic nose.
Reference lists were reviewed for additional references.
Study selection and data extraction
Figure 4 illustrates a flow-chart of the study selection [16].
Controlled, clinical studies, with full text in English,
exploring the diagnostic and monitoring value of VOCs in
asthma, COPD, CF, lung cancer and respiratory tract
infections were included. In vitro studies were excluded.
Data on study design, setting, participant characteristics,
VOCs techniques, and outcome measures were extracted.
Due to expected heterogeneity of studies, no single scalehromatography (GC) technique, exhaled breath is collected and
l containers. Once the VOCs are collected and temporarily trapped,
rmal desorption. Subsequently, the analysis of individual molecular
y (GC-MS) or flame ionization detection (GC-FID). The diverse VOCs are
Distinct VOCs have dissimilar progression rates and reach the end of
retention time, VOCs can be identified in a mass-spectra library. The
alyzed with GC. The retention time (in minutes) is stated on the x axis,
s. Published in Robroeks et al. Pediatr Res 2010 [14].
Figure 3 Breath-print of VOCs by the electronic Nose. Breath samples can also be analyzed using an eNose. The eNose consists of an array of
nanosensors. When these sensors are exposed to a mixture of VOCs, a change in their electrical resistance is induced, leading to the production
of a ‘breath-print’. This breath-print represents the complex mixture of exhaled VOCs and can be used for pattern-recognition algorithms in
multiple diseases. A limitation of the eNose is that it is unable to analyze individual VOCs. In the figure two exhaled breath-prints analyzed with
the eNose are demonstrated (purple line represents sample 1, green line represents sample 2). The y axis represents the change in resistance
(Δ R/Rt = 0) of each of the 28 sensors (1–28). Courtesy: Paul Brinkman, Niki Fens, Peter Sterk, University of Amsterdam, the Netherlands.
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per study, criteria that are of importance to examine the
validity are described in Table 1.
Data synthesis and analysis
Evidence data were pooled by study design; studies
using: 1) single VOCs in diagnosing pulmonary diseases
(Table 2); 2) VOCs profiles in diagnosing pulmonary
diseases (Table 3); and 3) VOCs profiles in differential
diagnosing pulmonary diseases (Table 4).
Results
Description of included studies
Seventy-three studies were included of which the charac-
teristics are provided in Table 1. In total, nine studies
described VOCs in asthma, seven in COPD, seven in CF,
four compared asthma with COPD or CF, thirty-four in
thoracic cancer (of which 6 studies included COPD patients
in the control group), and twelve studies described VOCs
in other pulmonary diseases. A total of 2,973 healthy con-
trols and 3,952 patients were investigated; 417 asthmatic
patients, 527 COPD patients, 188 CF patients, 1,575 lung
cancer patients, 33 malignant pleural mesothelioma (MPM)patients, 139 subjects with an abnormal chest radiograph,
579 subjects suspected for pulmonary tuberculosis, and 494
patients with other (pulmonary) diseases (e.g. sarcoidosis,
acute respiratory distress syndrome). Various techniques
were described to collect and analyze exhaled VOCs. The
most commonly used technique was gas chromatography
(N = 50), usually combined with MS or FID. Fifteen studies
analyzed VOCs using an eNose, whilst thirteen studies used
PTR-MS, SIFT-MS, IMS, laser spectroscopy, colorimetric
sensor array, and/or GNPs (some studies used multiple
techniques). Forty-five studies were conducted in the last
five years. An overview of findings per study can be found
in Tables 2, 3, 4. The most important findings are sum-
marized below.
Volatile organic compounds in asthma
Several studies found that an accurate asthma diagnosis
was possible using profiles of VOCs (Table 3). Dragonieri
and Fens et al. demonstrated that a VOCs profile could
correctly classify asthmatic patients when using an eNose
[10,15]. Moreover, Montuschi and colleagues demonstrated
that VOCs profiling using an eNose had higher diagnostic
performance for asthma than exhaled nitric oxide or lung
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Figure 4 Flow-chart of literature search. Summary of evidence search and selection according to the Prisma flow-chart [16]. Abbreviations:
VOCs = Volatile Organic Compounds.
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http://respiratory-research.com/content/13/1/117function [22]. Dallinga and Caldeira et al. demonstrated
that VOCs profiling was able to accurately distinguish
children with asthma from controls [17-19]. With respect
to differential diagnosis, it was demonstrated that an eNose
VOCs profile was able to discriminate between asthma and
COPD patients (Table 4) [15,32]. An external validation
study demonstrated that not only ‘classical’ asthmatic
patients (with reversible airway obstruction) but also
asthmatic patients with fixed airway obstruction could be
distinguished from COPD patients [27]. As these latter two
groups usually have similar symptoms and overlapping
spirometry, differential diagnosis is often difficult. These
findings imply that VOCs profiling is of additional value in
the differential diagnosis of asthma and COPD.
Next to diagnosing asthma, VOCs might be useful in the
assessment of asthma severity and control. Paredi et al.
found elevated levels of exhaled ethane in steroid-naïve
asthmatics compared to steroid-treated asthmatics (Table 2).
Furthermore, ethane was higher in patients with severe
asthma (FEV1 < 60%), compared to patients with mild
asthma (FEV1 > 60%) [24]. In contrast, Dragonieri et al.
reported that it was not possible to adequately distinguish
mild and severe asthmatics using an eNose profile [10].
Regarding asthma control, higher exhaled pentane levelswere found in asthmatic patients with an exacerbation
compared to controls. Once the asthma exacerbation subsi-
dized, pentane levels decreased to levels comparable to
controls [23]. Moreover, Ibrahim demonstrated that VOCs
profiles were able to diagnose sputum eosinophilia and
identify patients with poor disease control [20]. Taken
together, VOCs profiling might be useful for an asthma
diagnosis, for differentiating asthma from COPD, and for
assessing asthma control. The usefulness of VOCs profiles
in assessing disease severity still needs to be established.
Volatile organic compounds in chronic obstructive
pulmonary disease
Many COPD patients are diagnosed at an advanced stage
of the disease, when benefits of interventions such as smo-
king cessation and drug therapy are less pronounced. An
early diagnosis of COPD would be an advantage. Multiple
research groups demonstrated that VOC profiles could
accurately differentiate COPD patients from healthy (non-)
smokers [25,29,31,33]. In contrast, others found a limited
performance of VOCs profiles to differentiate COPD
patients from (former) smokers [15,26]. Hattesohl et al.
demonstrated that eNose derived VOCs profiles were not
different between COPD patients with and without an
Table 1 Characteristics of included studies on VOCs in pulmonary diseases
Author
(year)





35 children with asthma, 15 healthy
controls





32 children with allergic asthma, 27
healthy controls





63 children with asthma, 57 healthy
controls






10 patients with mild asthma, 10 patients
with severe asthma, 20 healthy controls





35 patients with asthma, 23 healthy
controls





13 patients with asthma, 14 healthy
controls







27 patients with asthma, 24 healthy
controls










12 patients with acute asthma, 11
patients with stable asthma, 17 healthy
controls





26 patients with asthma, 14 healthy
controls












204 (former) smokers (43 with
emphysema/COPD)
Radboud University, Nijmegen (the Netherlands) PTR-MS Mass-spectra [26]
Fens (2009) Cross-sectional COPD vs.
asthma vs.
controls
30 patients with COPD, 20 patients with
asthma, 20 non-smoking controls, 20
smoking controls
Academic MC Amsterdam; Haga Teaching Hospital, The
Hague; Albert Schweitzer Hospital, Dordrecht (the
Netherlands)
eNose VOCs profile [15]
Fens (2011) Cross-sectional COPD vs.
asthma
40 patients with COPD, 21 patients with
fixed asthma, 39 patients with classic
asthma
Academic MC Amsterdam; Haga Teaching Hospital, The
Hague; Albert Schweitzer Hospital, Dordrecht (the
Netherlands)








10 patients with COPD with AAT
deficiency, 23 patients with COPD
without AAT deficiency, 10 healthy
controls





30 patients with COPD, 54 patients with
COPD + BC, 35 healthy controls





22 patients with COPD, 14 healthy
controls







119 patients with COPD, 63 healthy
controls




















17 patients with COPD, 20 patients with
asthma, 7 healthy controls





66 patients with COPD, 15 steroid naïve
COPD patients, 45 healthy controls
Maastricht University MC (the Netherlands) GC-MS VOCs profile [33]
Barker
(2006)
Cross-sectional CF vs. controls 20 patients with CF, 20 healthy controls Aachen CF center (Germany) GC-MS Set of 12 VOCs [34]
Enderby
(2009)
Cross-sectional CF vs. asthma 16 patients with CF, 21 patients with
asthma
University Hospital of North Staffordshire,Stoke-on-T nt (UK) SIFT-MS Hydrogen cyanide [35]
Gilchrist
(2012)
Cross-sectional CF with- vs. CF
without Ps.
infection
8 CF patients with Ps. infection, 7 CF
patients without Ps. infection
University Hospital of North Staffordshire,Stoke-on-T nt (UK) SIFT-MS Hydrogen cyanide [36]
Kamboures
(2005)













12 patients with CF, 12 healthy controls Queen’s University, Belfast (UK) GC-MS Isoprene [38]
Paredi
(2000)





Cross-sectional CF vs. controls 48 patients with CF, 57 healthy controls Maastricht University MC (the Netherlands) GC-MS VOCs profile [14]
Shestivska
(2011)
Cross-sectional CF vs. controls 28 patients with CF, 9 healthy controls Academy of Science of the Czech Republic, Prague zech
Republic)
GC-MS Methyl thiocyanate [40]
Bajtarevic
(2009)













LC vs. controls 11 patients with LC, 30 healthy controls Tampere University Hospital (Finland) GC-MS Pentane [43]
D’Amico
(2010)
Cross-sectional LC vs. no LC vs.
controls
28 patients with LC, 28 patients with
diverse lung diseases (e.g. COPD (n = 16),
bronchitis), 36 healthy controls





Cross-sectional LC vs. controls 35 patients with LC, 9 post-surgical LC
patients, 18 healthy controls





Cross-sectional LC vs. COPD vs.
controls
10 patients with NSCLC, 10 patients with
COPD, 10 healthy controls
Leiden University MC (the Netherlands) eNose VOCs profile [12]
Fuchs
(2010)
Cross-sectional LC vs. controls 12 patients with LC, 12 healthy smokers,
12 healthy controls



















Table 1 Characteristics of included studies on VOCs in pulmonary diseases (Continued)
Gaspar
(2009)
Cross-sectional LC vs. controls 18 patients with LC, 10 healthy controls University of Lisbon (Portugal) GC-MS VOCS profile [46]
Gordon
(1985)
Cross-sectional LC vs. controls 12 patients with LC, 9 healthy controls Michael Reese Hospital, Chicago (USA) GC-MS Set of 22 VOCs [47]
Kischkel
(2010)
Cross-sectional LC vs. controls 31 patients with LC, 31 healthy smokers,
31 healthy controls
University of Rostock (Germany) GC-MS Set of 42 VOCs [48]
Ligor (2009) Cross-sectional LC vs. controls 65 patients with LC, 31 healthy controls Innsbruck Medical University (Austria) GC-MS Set of 103 VOCs [49]
Machado
(2005)
Cross-sectional LC vs. no LC vs.
controls
28 patients with LC, 57 patients with
diverse lung diseases (e.g. COPD (n = 12),
asthma (n = 11), CBD), 50 healthy controls





Cross-sectional LC vs. no LC vs.
controls
49 patients with NSCLC, 73 patients with
diverse lung diseases (e.g. COPD (n = 18),
sarcoidosis), 21 healthy controls





Cross-sectional LC vs. controls 92 patients with LC, 59 healthy smokers,
78 patients with diverse lung diseases
(e.g. COPD (n = 8))





Cross-sectional LC vs. controls 40 patients with LC, 56 healthy controls Rambam Health Care Campus, Haifa (Israel) GNPs GC-MS VOCs profile [52]
Peng
(2010)
Cross-sectional LC vs. controls 30 patients with PLC, 22 healthy controls Rambam Health Care Campus, Haifa (Israel) GNPs GC-MS VOCs profile [53]
Phillips
(1999)
Cross-sectional LC vs. no LC 108 patients with abnormal chest
radiograph (60 patients with LC)
Penn State MC, Hershey (USA); Hammersmith Hospital,
London (UK); St. Vincent’s MC, New York (USA)
GC-MS VOCs profile [54]
Phillips
(2003)
Cross-sectional LC vs. no LC vs.
controls
178 patients with abnormal chest
radiograph (87 patients with LC), 41
healthy controls
Charing Cross Hospital, London (UK); Columbia Presbyterian
MC/New York University MC/St. Vincent’s MC, New York
(USA); Penn State MC, Hershey (USA)




Cross-sectional LC vs. controls 193 patients with PLC, 211 (former)
healthy smokers
Harper Hospital, Detroit; New York University MC/Columbia
University MC/Weill Medical College of Cornell University,
New York (USA); University of California, Los Angeles; Danbury
Hospital, Connecticut (USA).





LC vs. COPD vs.
controls
36 patients with NSCLC, 25 patients with
COPD, 35 healthy smokers, 50 healthy
non-smokers
University of Parma (Italy) GC-MS Set of 13 VOCs [57]
Poli (2008) Follow-up LC before vs.
after surgery
36 patients with NSCLC, 50 healthy
controls
University of Parma (Italy) GC-MS Set of 12 VOCs [58]
Poli (2010) Cross-sectional LC vs. controls 40 patients with NSCLC, 38 healthy
controls
University of Parma (Italy) GC-MS Set of 7 aldehydes [59]
















Table 1 Characteristics of included studies on VOCs in pulmonary diseases (Continued)
Rudnicka
(2011)
Cross-sectional LC vs. controls 23 patients with LC, 30 healthy controls Nicolaus Copernicus University, Torun (Poland) GC-MS Set of 55 VOCs [61]
Skeldon
(2006)
Cross-sectional LC vs. no LC vs.
controls
12 patients with LC, 40 patients with
diverse lung diseases, 58 healthy controls






Cross-sectional LC vs. controls 43 patients with NSCLC, 41 healthy
controls






Cross-sectional LC vs. controls 11 patients with LC, 57 healthy smokers Radboud University, Nijmegen (the Netherlands) PTR-MS Mass-spectra [64]
Ulanowska
(2011)
Cross-sectional LC vs. controls 137 patients with LC, 143 healthy controls Nicolaus Copernicus University, Torun (Poland) GC-MS VOCs profile [65]
Wehinger
(2007)
Cross-sectional LC vs. controls 17 patients with PLC, 170 healthy controls Innsbruck Medical University (Austria) PTR-MS Mass-spectra [66]
Westhoff
(2009)
Cross-sectional LC vs. controls 32 patients with LC, 54 healthy controls Hemer Lung Hospital (Germany) IMS VOCs profile [67]
Chapman
(2012)
Cross-sectional MPM vs. ARD vs.
controls
20 patients with MPM, 18 patients with
ARD, 42 healthy controls





Cross-sectional MPM vs. no
MPM
13 patients with MPM, 13 subjects with
long-term asbestos exposure, 13 healthy
controls






Cross-sectional A. fumigatus vs.
controls
32 patients with diverse lung diseases
(e.g. asthma (n = 11), CF (n = 6), COPD
(n = 3), 10 neutropenic patients, 14
healthy controls
University of Christchurch (New Zealand) GC-MS 2-Pentylfuran [71]
Hanson
(2005)
Cross-sectional VAP vs. no VAP 19 patients with + VAP score, 19 patients
with - VAP score
University of Pennsylvania, Philadelphia (USA) eNose VOCs profile [72]
Hockstein
(2004)
Cross-sectional VAP vs. no VAP 13 ventilated patients with VAP, 12
ventilated patients without VAP
University of Pennsylvania, Philadelphia (USA) eNose VOCs profile [73]
Hockstein
(2005)
Cross-sectional VAP vs. no VAP 15 patients with + VAP score, 29 patients
with - VAP score






ILD vs. controls 34 patients with ILD, 16 healthy controls National Defense Medical College, Saitama (Japan) GC-FID Ethane [75]
Kolk (2012) Cross-sectional TB vs. no TB 171 patients suspected of TB Royal Tropical Institute, Amsterdam (the Netherlands);
Desmond Tutu TB Centre, Cape Town (South Africa)
GC-MS VOCs profile [76]
Phillips
(2007)
Cross-sectional TB vs. no TB vs.
controls
42 patients suspected of TB, 59 healthy
controls
Bellevue Hospital, New York (USA) GC-MS VOCs profile [77]
Phillips
(2010)
Cross-sectional TB vs. no TB 226 patients suspected of TB University of California, San Diego (USA); University of Santo
Tomas, Manila (Philippines), De La Salle University Hospital,
Cavite (Philippines), East London Tuberculosis Service (UK)














Table 1 Characteristics of included studies on VOCs in pulmonary diseases (Continued)
Phillips
(2012)
Cross-sectional TB vs. controls 130 patients with TB, 121 healthy controls University of Santo Tomas, Manila (Philippines); De La Salle
University Hospital, Cavite (Philippines); Homerton University
Hospital, London (UK); Hinduja Hospital, Mumbai (India)
GC-SAW VOCs profile [79]
Syhre
(2009)
Cross-sectional TB vs. controls 10 patients with TB, 10 healthy controls Otago University, Christchurch (New Zealand); Modilon
Hospital, Madang (Papua New Guinea)






65 critically ill patients (n = 19 with head
injury, n = 13 with ARDS, n = 33 at risk of
ARDS), 10 healthy controls












19 critically ill patients with ARDS, 18
critically ill patients without ARDS





Abbreviations: AAT deficiency = Alpha 1-antitrypsin deficiency; A. fumigatus = Aspergillus fumigatus; ARD = Benign Asbestos-Related Diseases; ARDS = Acute Respiratory Distress Syndrome; BC = Bronchial
Carcinoma; CBD = Chronic pulmonary Beryllium Disease; CF = Cystic Fibrosis; Classic asthma = Asthmatics with reversible airway obstruction; COPD = Chronic Obstructive Pulmonary Disease; DMS = Differential
Mobility Spectrometry; eNose = electronic Nose; FID = Flame Ionization Detector; Fixed asthma = Asthmatics with fixed airway obstruction; GC = Gas Chromatography; GNPs = Gold Nano Particles sensors; ILD =
Interstitial Lung Disease (e.g. sarcoidosis, idiopathic pulmonary fibrosis, cryptogenic organizing pneumonia); IMS = Ion Mobility Spectrometry; LC = Lung Cancer; MC =Medical Centre; MPM =Malignant Pleural
Mesothelioma; MS =Mass Spectrometry; NSCLC = Non-Small Cell Lung Cancer; OFD = On-Fiber-Derivatization; P. infection = Pseudomonas aeruginosa infection; PLC = Primary Lung Cancer; PTR-MS = Proton Transfer















Table 2 Studies using single VOCs for the diagnosis of various pulmonary diseases (diseased vs. healthy controls)
Author
(year)
Marker Disease N Value Unit Diff. Value marker Unit Controls N p-value Ref.
Lärstad
(2007)
Ethane Asthma 13 N.S. = N.S. Controls 14 p > 0.05 [21]
Pentane N.S. = N.S. p > 0.05
Isoprene 113 ppb∞ < 143 ppb∞ p < 0.05
Olopade
(1997)
Pentane Acute asthma 12 8.4 ± 2.9 nmol/L* > 2.6 ± 0.2 nmol/L* Controls 17 p < 0.05 [23]










12 2.77 ± 0.25 ppb* > 0.88 ± 0.09 ppb* Controls 14 p < 0.05 [30]
Barker
(2006)
Pentane** CF 20 0.36 (0.24-0.48) ppb# > 0.21 (0.13-0.29) ppb# Controls 20 p < 0.05 [34]
Dimethyl Sulphide** 3.89 (2.24-5.54) ppb# < 7.58 (5.73-9.43) ppb# p < 0.01
Ethane** 0.39 (−0.04-0.82) ppb# = 0.10 (−0.25-0.44) ppb# p > 0.05
Propane, methanol, ethanol, acetone,
isoprene, benzene, toluene, limonene
- = - p > 0.05
Kamboures
(2005)
Carbonyl sulphide** CF 20 - 110 ± 60 pptv# > - 250 ± 20 pptv# Controls 23 p < 0.001 [37]
Dimethyl sulphide 4,780 ± 1,350 pptv# = 3,920 ± 680 pptv# p > 0.05





12 125 ± 23 pmol·min·kg-
1*
< 164 ± 20 pmol·min·kg-
1*
Controls 12 p < 0.05 [38]
Isoprene CF after
exacerbation
12 188 ± 23 pmol·min·kg-
1*
= 164 ± 20 pmol·min·kg-
1*





23 1.99 ± 0.20 ppb* > 0.82 ± 0.09 ppb* Controls 14 p < 0.05 [39]
Shestivska
(2011)
Methyl thiocyanate CF 28 7 (2–21) ppbv~ = 8 (5–8) ppbv°° Controls 9 p > 0.05 [40]
Bajtarevic
(2009)
Isoprene LC 220 81.5 ppb∞ < 105.2 ppb∞ Controls 441 p < 0.01 [41]
Acetone 458.7 ppb∞ < 627.5 ppb∞ p < 0.01
Methanol 118.5 ppb∞ < 142.0 ppb∞ p < 0.05
Buszewski
(2012)
Acetone LC 29 34.57-390.60 ppb° ? 44.20-531.45 ppb° Controls 44 p < 0.05 [42]
Benzene 1.29-3.82 ppb° ? 1.38-14.97 ppb° p < 0.05
Butanal 1.32-2.55 ppb° > 1.35-1.87 ppb° p < 0.01














Table 2 Studies using single VOCs for the diagnosis of various pulmonary diseases (diseased vs. healthy controls) (Continued)
Ethyl acetate 3.98-22.89 ppb° > 1.12-8.22 ppb° p < 0.01
Ethyl benzene 1.45-3.16 ppb° ? 2.22-18.38 ppb° p < 0.01
2-Pentanone 3.25-8.77 ppb° > 1.80-4.11 ppb° p < 0.01
Propanal 1.56-3.74 ppb° > 1.56-3.44 ppb° p < 0.01
1-Propanol 4.37-13.15 ppb° > N.S. ppb° p < 0.01
2-Propanol 3.32-7.19 ppb° > 3.21-4.17 ppb° p < 0.01
2-Propenal 6.84-94.36 ppb° > 5.10-9.57 ppb° p < 0.05
Other VOCs N.S. ppb° = N.S. ppb° p > 0.05
Crohns
(2009)
Pentane** LC 11 1.73 (1.05-2.86) ng/L# > 0.83 (0.61-1.13) ng/L# Controls 30 p < 0.05 [43]
Fuchs
(2010)
Pentanal** LC 12 0.019 (0.011-0.031) nmol/Lˆ > 0.002 (0.000-0.011) nmol/Lˆ Controls 12 p < 0.05 [45]
Hexanal** 0.010 (0.008-0.026) nmol/Lˆ > 0.000 (0.000-0.001) nmol/Lˆ p < 0.05
Octanal** 0.052 (0.026-0.087) nmol/Lˆ > 0.011 (0.004-0.028) nmol/Lˆ p < 0.05
Nonanal** 0.239 (0.128-0.496) nmol/Lˆ > 0.033 (0.021-0.096) nmol/Lˆ p < 0.05
Acetaldehyde**, Propanal, butanal**,
heptanal, decanal**
- = - p > 0.05
Kischkel
(2010)
Dimethyl sulphide** LC 31 0.27 (0.00-0.27) nmol/Lˆ < 0.30 (0.00-0.31) nmol/Lˆ Controls 31 p < 0.01 [48]
Dimethyl formamide** 1855 (0.00-
3340.88)
(counts)ˆ > 0.00 (0.00-2954.13) (counts)ˆ p < 0.05
Butane** 0.00 (0.00-0.11) nmol/Lˆ > 0.18 (0.00-0.52) nmol/Lˆ p < 0.01
Butanal** 1.07 (0.38-3.51) nmol/Lˆ > 0.32 (0.00-1.40) nmol/Lˆ p < 0.001
Other VOCs (N = 38) N.S. N.S p > 0.05
Poli (2005) 2-Methylpentane NSCLC 36 139.5 (65.7-298.8) 10-12Mˆ > 27.7 (3.4-50.3) 10-12Mˆ Controls 50 p < 0.001 [57]
Pentane 647.5 (361.3-
1112.5)
10-12Mˆ > 268.0 (107.7-462.7) 10-12Mˆ p < 0.001
Ethylbenzene 24.0 (13.6-32.6) 10-12Mˆ > 13.6 (10.8-15.1) 10-12Mˆ p < 0.01
Xylenes 68.9 (43.6-108.4) 10-12Mˆ > 31.1 (21.1-56.4) 10-12Mˆ p < 0.001
Trimethylbenzene 14.9 (9.3-22.1) 10-12Mˆ > 6.2 (4.7-11.0) 10-12Mˆ p < 0.01
Toluene 158.8 (118.7-237.5) 10-12Mˆ > 80.8 (58.9-140.0) 10-12Mˆ p < 0.001
Benzene 94.5 (62.2-132.2) 10-12Mˆ > 44.7 (27.7-68.6) 10-12Mˆ p < 0.001
Decane 568.0 (277.9-
1321.6)
10-12Mˆ > 208.7 (14.3-405.5) 10-12Mˆ p < 0.001
Octane 61.0 (22.4-112.9) 10-12Mˆ > 20.2 (4.0-50.8) 10-12Mˆ p < 0.001














Table 2 Studies using single VOCs for the diagnosis of various pulmonary diseases (diseased vs. healthy controls) (Co inued)
Isoprene, heptane, styrene - = - p > 0.05
Poli (2008) 2-Methylpentane NSCLC (3 yrs
after surgery)
10 87.9 (35.5-278.9) 10-12Mˆ > 27.7 (3.4-50.3) 0-12Mˆ Controls 50 p < 0.05 [58]
Pentane 1569.0 (497.9-
3214)
10-12Mˆ > 268.0 (107.7-462.7) 0-12Mˆ p < 0.001
Ethylbenzene 46.4 (38.6-90.9) 10-12Mˆ > 13.6 (10.8-15.1) 0-12Mˆ p < 0.001
Xylenes 56.2 (38.9-80.4) 10-12Mˆ > 31.1 (21.1-56.4) 0-12Mˆ p < 0.05
Trimethylbenzene 15.3 (11.7-22.3) 10-12Mˆ > 6.2 (4.7-11.0) 0-12Mˆ p < 0.001
Toluene 297 (202.6-297.0) 10-12Mˆ > 80.8 (58.9-140.0) 0-12Mˆ p < 0.001
Pentamethylheptane 8.8 (2.2-15.2) 10-12Mˆ > 0.9 (0.1-2.6) 0-12Mˆ p < 0.001
Isoprene 678.9 (359.8-
1111.0)
10-12Mˆ < 3789 (1399–6589) 0-12Mˆ p < 0.01
Benzene, Heptane, Octane, Styrene - = - p > 0.05
Preti (1988) O-toluidine LC 10 N.S > N.S Controls 16 p < 0.05 [60]
Aniline N.S = N.S p > 0.05
Rudnicka
(2011)
Propane LC 23 3.19-9.74 ppb° > 3.45-5.96 pb° Controls 30 p < 0.05 [61]
2-Propenal N.S ? N.S p < 0.05
Carbon disulfide N.S ? N.S p < 0.05
Isopropyl alcohol N.S ? N.S p < 0.05
Ethylbenzene 1.45–3.16 ppb° < 2.22–18.38 pb° p < 0.05
Styrene N.S ? N.S p < 0.05
Other VOCs (N = 49) N.S = N.S p > 0.05
Skeldon
(2006)
Ethane** LC 12 0.7 (0–7.6) ppb~ = 1.9 (0–10.54) pb~ Controls 12 p > 0.05 [62]
Song
(2010)
1-Butanol** NSCLC 43 6.36 (12.93) ng/Lˆ > 2.18 (2.06) g/Lˆ Controls 41 p < 0.001 [63]
3-Hydroxy-2-butanone** 8.28 (11.52) ng/Lˆ > 1.29 (2.01) g/Lˆ p < 0.001
Ulanowska
(2011)
Ethanol** LC 137 466.9 (12.8-1520.1) ppb°° > 188.5 (4.5-479.5) pb°° Controls 86 p < 0.05 [65]
Acetone** 358.6 (112.3-
2653.7)
ppb°° > 225.7 (41.6-753.4) pb°° p < 0.05
Butane** 90.3 (6.1-421.3) ppb°° > 56.2 (5.2-165.7) pb°° p < 0.05
Dimethyl sulphide** 11.9 (6.3-18.5) ppb°° > 9.3 (5.3-19.3) pb°° p < 0.05
Isoprene** 100.3 (19.2-295.5) ppb°° > 70.8 (19.5-200.5) pb°° p < 0.05
Propanal** 7.8 (5.5-33.8) ppb°° > 6.9 (5.6-9.1) pb°° p < 0.05


































Table 2 Studies using single VOCs for the diagnosis of various pulmonary diseases (diseased vs. healthy controls) (Continued)
2-Pentanone** 7.5 (4.4-53.2) ppb°° > 4.8 (4.6-5.1) ppb°° p < 0.05
Furan** 4.7 (3.1-7.0) ppb°° > 3.7 (3.0-5.3) ppb°° p < 0.05
o-Xylene** 22.1 (7.6-95.2) ppb°° > 17.4 (6.2-30.8) ppb°° p < 0.05
Ethylbenzene** 19.6 (4.6-89.3) ppb°° > 10.4 (8.6-14.0) ppb°° p < 0.05
Other VOCs (N ≈ 20) - = - p > 0.05
Wehinger
(2007)
Formaldehyde PLC 17 7.0 (15.5) ppbˆ > 3.0 (1.9) ppbˆ Controls 170 p < 0.001 [66]
Propanol 244.1 (236.2) ppbˆ > 94.1 (55.2) ppbˆ p < 0.001
Isoprene 52.1 (26.7) ppbˆ < 81.8 (56.1) ppbˆ p < 0.01
Acetone, o-Toluidine - = - p > 0.05
Gennaro
(2010)
Cyclohexane** MPM 13 251.79 (84%) ng/L∂ > 33.08 (58%) ng/L∂ Controls 13 p < 0.05 [70]
Other VOCs (N = 19) - = - p > 0.05
Syhre
(2009)
Methyl nicotinate TB 10 N.S > N.S Controls 10 p < 0.01 [80]
Chambers
(2009)
2-Pentylfuran*** A. fumigatus 17 Sens: 77, Spec: 78 % > Not detected Controls 14 N.S. [71]
Kanoh
(2005)
Ethane** ILD 34 8.5 ± 8.0 pmol/dL* > 2.9 ± 1.0 pmol/dL* Controls 16 p < 0.001 [75]
Scholpp
(2002)
Acetone ARDS 13 50.0 (19.6-72.3) nmol/Lˆ = 33.2 (20.8-38.6) nmol/Lˆ Controls 10 p > 0.05 [81]
Isoprene 2.18 (1.1-3.89) nmol/L# < 5.99 (3.53-8.45) nmol/L# p < 0.05
n-Pentane 1.00 (0.26-1.72) nmol/Lˆ > 0.12 (0.10-0.16) nmol/Lˆ p < 0.05
n-Pentane At risk ARDS 33 0.49 (0.30-0.99) nmol/Lˆ > 0.12 (0.10-0.16) nmol/Lˆ Controls 10 p < 0.05
Schubert
(1998)
Acetone ARDS 19 149 (113–485) nmol/m2 ≈ = 119 (52–270) nmol/m2≈ No
ARDS
18 p > 0.05 [82]
Isoprene 9.8 (8.2-21.6) nmol/m2 ≈ < 21.8 (13.9-41.4) nmol/m2≈ p < 0.05
n-Pentane 4.2 (3.7-9.3) nmol/m2 ≈ = 5.1 (1.4-18.6) nmol/m2≈ p > 0.05
Data are presented as; *mean ± SEM or SD; #mean (95% confidence interval);∞median; ˆmedian (25th-75th percentile); ~median (range); ≈median (95% confidence interval); ° range; °° mean (range);
∂ median (relative standard deviation). ** Exhaled concentrations corrected for ambient concentrations (e.g. subtraction, VOCs filter). *** Sensitivity and specificity 2-Pentylfuran compared with gold standard (sputum).
Diff. = Difference between diseased and controls: > elevated in diseased vs. controls, = no difference in diseased vs. controls, < decreased in diseased vs. controls. Abbreviations: A. fumigatus = Aspergillus fumigatus;
ARDS = Acute Respiratory Distress Syndrome; CF = Cystic Fibrosis; COPD = Chronic Obstructive Pulmonary Disease; ILD = Interstitial Lung Disease (e.g. sarcoidosis, idiopathic pulmonary fibrosis, cryptogenic organizing














Table 3 Studies using VOCs profiles for the diagnosis of various pulmonary diseases (diseased vs. healthy controls)
Author (year) Disease N Discriminative Controls N No. of markers Sensitivity/Specificity (%)* Ref.
Caldeira (2011) Asthma 35 + Controls 15 28 CVV: 88% [17]
Caldeira (2012) Asthma 32 + Controls 27 9 98/93 [18]
Dallinga (2010) Asthma 63 + Controls 57 8 to 22 89 - 100/95 - 100 [19]
Dragonieri (2007) Mild asthma 10 + Controls 10 N.S. CVV: 100% (M-distance 5.32) [10]
Severe asthma 10 + Controls 10 N.S. CVV: 90% (M-distance 2.77)
Fens (2009) Asthma 20 + Non-smoking controls 20 N.S. CVV: 95% (p < 0.001) [15]
Asthma 20 + Smoking controls 20 N.S. CVV: 93% (p < 0.001)
Ibrahim (2011) Asthma 35 + Non-smoking controls 23 15 CVV: 83% (PPV: 0.85, NPV: 0.89) [20]
Montuschi (2010) Asthma 27 + Controls 24 N.S. DP: 88% [22]
Timms (2012) Asthma 20 + Controls 7 N.S. CVV: 70% (p = 0.047) [32]
COPD 17 + Controls 7 N.S. M-distance: 3.601 (p < 0.01)
Cristescu (2011) Emphysema 43 - (Former) smoking controls 161 1 AUC: 0.56 (CI: 0.45-0.66) [26]
Basanta (2010) COPD 20 + Smoking controls 6 N.S. 88/81 [25]
Fens (2009) COPD 30 +/− Smoking controls 20 N.S. CVV: 66% (p < 0.01) [15]
COPD 30 - Non-smoking controls 20 N.S. CVV: N.S.
Hattesohl (2011) COPD 23 +/− Controls 10 N.S. CVV: 68% (p < 0.001) [28]
Hauschild (2012) COPD 84 + Controls 35 120 87 - 98/71 - 86 [29]
Phillips (2012) COPD 119 + Controls 63 N.S. 79/64 [31]
Van Berkel (2010) COPD 50 + Controls 29 6 to 13 98 - 100/88 - 100 [33]
COPD (validation) 16 + Controls (validation) 16 6 100/81
Robroeks (2010) CF 48 + Controls 57 22 100/100 [14]
Bajtarevic (2009) LC 65 + Controls 31 15 to 21 71 - 80/100 - 100 [41]
D’Amico (2010) LC 28 + Controls 36 N.S. 85/100 [44]
Di Natale (2003) LC 35 + Controls 18 N.S. 100/94 [11]
Dragonieri (2009) NSCLC 10 + Controls 10 N.S. CVV: 90% (M-distance 2.96) [12]
Gaspar (2009) LC 18 + Controls 10 10 100/100 [46]
Gordon (1985) LC 12 + Controls 9 22 DP > 80% [47]
Ligor (2009) LC 65 +/− Controls 31 8 51/100 [49]
Machado (2005) LC 14 + Controls 20 N.S. CVV: 72% (M-distance: 3.25) [13]
Mazzone (2007) NSCLC 49 - Controls 21 N.S. 57/78 [50]
Peng (2009) LC 40 + Controls 56 42 2 PCA clusters: 100% discrimination [52]
Peng (2010) PLC 30 + Controls 22 33 2 PCA clusters: 100% discrimination [53]














Table 3 Studies using VOCs profiles for the diagnosis of various pulmonary diseases (diseased vs. healthy controls) (Continued)
Phillips (2007–2008) PLC 193 + Controls 211 16 to 30 85 - 85/80 - 81 [55], [56]
Poli (2010) NSCLC 40 + Controls 38 7 90/92 [59]
Steeghs (2007) LC 11 + Controls 57 2 AUC: 0.81 [64]
Westhoff (2009) LC 32 + Controls 54 23 100/100 [67]
Chapman (2012) MPM 10 + Controls 32 N.S. 90/91 [68]
Dragonieri (2012) MPM 13 + Controls 13 N.S. CVV: 85% (p < 0.001) [69]
Phillips (2007) Patients suspected of TB 42 + Controls 59 N.S. (≈7) 100/100 [77]
Phillips (2012) Patients with TB 130 +/− Controls 121 8 71/72 [79]
*Sensitivity/Specificity (in %), unless stated otherwise. AUC = Area Under the ROC Curve; CF = Cystic Fibrosis; CI = 95% Confidence interval; COPD = Chronic Obstructive Pulmonary Disease; CVV = Cross-Validated
accuracy-Value; DP = Diagnostic Performance; LC = Lung Cancer; M-distance =Mahalanobis-distance; MPM =Malignant Pleural Mesothelioma; N = Sample size; NPV = Negative Predictive Value; N.S. = Not Stated;














Table 4 Studies using VOCs profiles for the differential diagnosis of various pulmonary diseases
Author (year) Disease I N Discriminative Disease II N No. of markers Sensitivity/Specificity (%)* Ref.
D’Amico (2010) LC 28 + Other lung diseases 28 N.S. 93/79 [44]
Dragonieri (2007) Mild asthma 10 +/− Severe asthma 10 N.S. CVV: 65% (M-distance 1.23) [10]
Fens (2009) Asthma 20 + COPD 30 N.S. CVV: 96% (p < 0.001) [15]
Fens (2011) ** Fixed Asthma 21 + COPD 40 N.S. 85/90 (CVV: 88%, p < 0.001) [27]
Classic Asthma 39 + 91/90 (CVV: 83%, p < 0.001)
Ibrahim (2011) Controlled Asthma 17 + Uncontrolled asthma 18 13 89/88 (PPV: 0.89, NPV: 0.88) [20]
Timms (2012) Asthma 20 + COPD 17 N.S. CVV: 70% (p < 0.05) [32]
Asthma 11 + Asthma with GER 9 CVV: 85% (p < 0.05)
COPD 8 +/- COPD with GER 9 CVV: 65 (p < 0.05)
Hattesohl (2011) COPD without AAT deficiency 23 +/- COPD with AAT deficiency 10 N.S. CVV: 58% (M-distance: 2.27) [28]
Dragonieri (2009) LC 10 + COPD 10 N.S. CVV: 85% (M-distance: 3.73) [12]
Machado (2005) LC (validation) 14 +/- No LC 62 N.S. 71/92 [13]
Mazzone (2007) LC 49 +/− No LC 94 N.S. 73/72 [50]
Mazzone (2012) NSCLC 83 + No LC 137 N.S. 70/86 [51]
Adenocarcinoma 50 + No LC 137 80/86
Squamous cell 23 + No LC 137 91/73
Adenocarcinoma 50 + Squamous cell 22 90/83
Phillips (1999) LC 60 +/− No LC 48 22 72/67 [54]
Phillips (2003) MLC 15 - No MLC 91 9 67/37 [7]
Poli (2005) NSCLC 36 + No LC 110 13 72/94 [57]
Chapman (2012) MPM 10 + ARD 18 N.S. 90/83 [68]
Dragonieri (2012) MPM 13 + No MPM 13 N.S. CVV: 81% (p < 0.001) [69]
Hanson (2005) + VAP score 19 + - VAP score 19 N.S. R2 (to standard): 0.81 (p < 0.0001) [72]
Hockstein (2004) VAP 13 + No VAP 12 N.S. CVV: >80% [73]
Hockstein (2005) + VAP score 15 +/− - VAP score 29 N.S. CVV: 66-70% [74]
Kolk (2012) TB 50 + No TB 50 7 72/86 [76]
TB (validation) 21 + No TB 50 7 62/84
Phillips (2007) TB 23 + No TB 19 N.S. (≈14) 96/79 [77]
Phillips (2010) TB N.S. + No TB N.S. N.S. (≈10) 84/65 [78]
*Sensitivity/Specificity (in %), unless stated otherwise. AAT deficiency = Alpha 1-antitrypsin deficiency; ARD = benign asbestos-related diseases; Classic asthma = Asthmatics with reversible airway obstruction; COPD =
Chronic Obstructive Pulmonary Disease; CVV = Cross-Validated accuracy-Value; DP = Diagnostic Performance; Fixed asthma = Asthmatics with fixed airway obstruction; GER = Gastro-Esophageal Reflux; LC = Lung
Cancer; M-distance =Mahalanobis-distance; MLC =Metastatic Lung Cancer; MPM =Malignant Pleural Mesothelioma; N = Sample size; NPV = Negative Predictive Value; N.S. = Not Stated; NSCLC = Non-Small Cell Lung
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validation. Moreover, cross-validated VOCs profiles of AAT
deficiency patients did not differ after human recombinant
AAT therapy [28].
Next to diagnostic purposes, VOCs might be useful to
monitor severity and inflammation status in COPD
patients. Elevated levels of ethane were found in steroid-
naïve COPD patients and patients with low FEV1 values
compared to steroid-treated patients and patients with
higher FEV1 values [30]. Fens et al. demonstrated that
VOCs profiles were associated with both cell counts and
sputum markers of inflammatory cell activation (eosino-
philic vs. neutrophilic) in COPD patients [83]. These
findings indicate that VOCs profiles might monitor both
type and activity of airway inflammation.
Volatile organic compounds in cystic fibrosis
In CF, there is less need for a new diagnostic tool as the
sweat chloride test and genetic screening serve as gold
standards. However, there is need for new tools regarding
early detection of Pseudomonas (P.) aeruginosa and predic-
tion and follow-up of exacerbations. Robroeks et al. demon-
strated that a VOCs profile could accurately discriminate
between CF patients with and without P. aeruginosa
colonization [14]. Gilchrist et al. showed that exhaled
hydrogen cyanide (a marker of P. aeruginosa) was elevated
in CF children with P. aeruginosa colonization compared to
CF children without colonization [36]. Accordingly,
Enderby et al. demonstrated that exhaled hydrogen cyanide
was elevated in children with CF compared to children with
asthma [35]. Kamboures et al. demonstrated elevated
levels of exhaled sulphides (produced by bacteria such as
P. aeruginosa) in CF patients compared to controls [37].
In contrast, Shestivska et al. could not demonstrate dif-
ferent levels of exhaled methyl thiocyanate (also a marker
of P. aeruginosa) in CF patients and controls [40].
Regarding monitoring disease control, McGrath
et al. demonstrated that CF patients with an acute ex-
acerbation had lower levels of exhaled isoprene com-
pared to controls [38]. When these patients were
treated with antibiotics, their isoprene levels increased
to normal [38]. Moreover, elevated ethane levels were
found in steroid-naïve CF patients compared to
steroid-treated patients [39]. In addition, elevated
pentane levels were found in CF patients with an
exacerbation [34]. These data demonstrate that
VOCs profiling can be useful for assessment and
follow-up of exacerbations, and for a rapid detection
of P. aeruginosa in CF patients.
Volatile organic compounds in thoracic oncology
The majority of lung cancer (LC) patients studied had
non-small cell lung cancer (Table 1). Several studies
demonstrated that a combination of VOCs, identified byGC-MS, could differentiate LC patients from controls
[7,41,46,47,49,52,53,55,56,59]. In general, the number of
VOCs per model ranged from 7 to 33, with a sensitivity
of 50-100% and a specificity of 80-100% (Table 3). These
studies, together with studies investigating single VOCs,
revealed that the discriminative VOCs were predominantly
alkanes (e.g. pentane, butane, propane), alkane derivates
(e.g. propanol, multiple aldehydes) and benzene derivates
(e.g. ethyl-, propylbenzene) (Table 2) [42,43,45,48,57,
59-63,65,66]. Although most VOCs levels were elevated,
certain levels (e.g. of isoprene) were decreased in patients
compared to controls [41,58,66]. The diagnostic potential
of VOCs profiles in LC was also demonstrated by
groups that used eNose and other sophisticated techni-
ques [11-13,44,51-53,64,67]. Moreover, breath profiles
were different in patients with dissimilar histology
(adenocarcinoma vs. squamous cell carcinoma) [51].
Besides, Peng et al. demonstrated distinct VOCs profiles
in patients with lung, colon, breast, and prostate cancer
[53]. The important findings of VOC signatures of different
cancer types, need to be confirmed in wider clinical studies.
Multiple studies investigated the potential of VOCs to
discriminate between LC and other pulmonary diseases.
Not single compounds (such as ethane), but a combination
of multiple VOCs was able to distinct LC patients from
patients with non-cancer pulmonary diseases (such as
COPD, pleurisy, idiopathic fibrosis) with a reasonable
accuracy (Table 4) [12,13,44,50,57,62]. Phillips et al. demon-
strated that primary LC could be reasonably diagnosed in
subjects with an abnormal chest radiograph [7,54]. How-
ever, VOCs had limited predictive value to stage LC
patients [7,63,84].
Two studies described the potential of VOCs in evalu-
ating treatment in LC patients. Poli et al. demonstrated
that VOCs levels, except for isoprene, were unaffected
one month after surgical resection of the tumor [58]. After
three years, several VOCs either increased (e.g. pentane) or
decreased (e.g. isoprene) compared to baseline [58]. How-
ever, most post-surgical VOCs levels remained higher com-
pared to levels of controls. Likewise, Crohns et al. were not
able to detect changes of pentane levels after radiotherapy,
although they did demonstrate that higher pre-treatment
levels predicted better survival [43].
Malignant pleural mesothelioma (MPM) is a rare tumor
mainly caused by asbestos exposure. VOCs profiles were
able to diagnose MPM in a group of subjects with long-
term professional asbestos exposure [68,69]. Moreover, de
Gennaro et al. distilled cyclohexane as possible marker of
MPM [70].
Smoking status can be an important influencing factor,
especially in patients with LC and COPD. Smoke contains
profuse amounts of VOCs and is associated with alterations
in exhaled VOCs patterns. As high background of external
VOCs caused by smoking can influence the accuracy of
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and COPD took smoking status into account in their
analysis [15,25,27,31,33,43,50,53-55,59,65].
Volatile organic compounds in other pulmonary diseases
VOCs were also studied in critically ill patients with acute
respiratory distress syndrome (ARDS). Lower isoprene
levels and elevated pentane levels were reported in ARDS
patients compared to controls [81,82]. These findings are
in line with the findings that critically ill patients with
ventilator-associated pneumonia (VAP) had decreased
isoprene levels and increased pentane levels compared to
patients without pneumonia [82]. In addition, VOCs pro-
files generated with the eNose had potential to diagnose
this form of pneumonia [72-74].
Kanoh et al. demonstrated that exhaled ethane was ele-
vated in patients with an interstitial lung disease (including
sarcoidosis and idiopathic pulmonary fibrosis) compared to
controls, with highest levels in those with an active and
progressive disease [75]. A small VOC, 2-pentylfuran, was
commonly present in breath of patients with a chronic pul-
monary disease (including asthma and CF) with Aspergillus
fumigatus in their respiratory specimens, whereas this VOC
was not detected in breath of controls [71]. Syhre et al.
demonstrated elevated levels of exhaled methyl nicotinate
(a volatile metabolite produced by M. tuberculosis) in
patients with pulmonary tuberculosis (TB) compared to
healthy controls [80]. In a group of patients with suspicion
of TB, VOC patterns were able to distinguish patients with
TB from those without active TB and healthy controls with
a reasonable accuracy (Table 4) [76-79].
Discussion
Conclusions from this review
A substantial increase in clinical studies on VOCs in pul-
monary diseases was observed in the last decade. Initial
studies on VOCs identified biomarkers in a traditional
way by focusing on single compounds based on biological
insight. Levels of several VOCs were demonstrated to be
distinct in people with a pulmonary disease compared to
controls. These markers mainly included alkanes for
asthma and COPD; alkanes, alkenes and alkene-derivates
for CF and analogous compounds plus benzene derivates
and aldehydes in lung cancer. Due to overlap in markers,
one may argue that a disease specific biomarker is not
discovered yet. For example, ethane was not only elevated
in asthmatic patients, but also in COPD and CF patients.
Similarly, decreased levels of isoprene were found in both
children with CF, asthmatic patients, lung cancer patients
and in patients with ARDS. Despite the lack of a single
discriminative biomarker, these studies did demonstrate
that exhaled breath of patients with a particular lung
disease is distinct from healthy controls. This finding
evolved in a new hypothesis that pulmonary diseases arecharacterized by a distinctive breath-print that is not
based on single markers, but on a profile of numerous
VOCs. Instead of a knowledge based strategy, recent stu-
dies mainly support an inductive strategy to discover
disease-specific VOCs profiles. Owing to recent technical
and analytical advancements, hundreds of VOCs can be
analyzed to characterize the breath-print of a pulmonary
disease. Various research groups demonstrated that, either
by using the eNose or GC, VOCs profiles of patients with
several pulmonary diseases could be well distinguished
from VOCs profiles of controls. Moreover, distinct VOCs
profiles were found in patients with dissimilar pulmonary
diseases. These promising results pave the way for the
development of a non-invasive diagnostic tool based on
exhaled VOCs.Potential applications and advantages of using VOCs into
clinical practice
Although current research mainly focused on the diagnos-
tic potential of VOCs, there are multiple other conceivable
applications of VOCs in the field of pulmonary diseases,
such as:
– (early) Diagnosing of pulmonary diseases (e.g. early
asthma diagnosis in children).
– Differential diagnosing (e.g. asthma versus COPD).
– Phenotyping within a pulmonary disease (e.g.
wheezing phenotypes in children).
– Monitoring disease severity and control.
– Predicting exacerbations and prognosis of a disease.
– Evaluating treatment/surgery (e.g. checking
compliance with prescribed medication).
– Screening for different diseases in population based
studies (e.g. predicting risk).
The advantages of VOCs profiling are evident. Although
VOCs can have an exogenous origin, numerous VOCs are
formed within the airways as a result of local inflammatory
or neoplastic processes. Therefore, the analysis of exhaled
VOCs can serve as a direct measure of lung status. Never-
theless, since VOCs are blood-borne they can also reflect
other processes in the body and thus may assess different
body functions in a flexible manner. Secondly, collection of
breath samples is safe, non-invasive and easy to perform
even in children and more severe patients. Breath collection
does not require skilled medical staff and obtaining large
quantities or repeated measurements are not as bother-
some for patients compared to e.g. blood sampling, sputum
induction or bronchoalveolar lavages. Moreover, the matrix
of exhaled breath is less complex than blood or urine,
eliminating the need for complicated work-up of samples.
Finally, techniques to measure VOCs, such as GC-MS, are
very sensitive to detect compounds and techniques such
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Challenges before VOCs can be used into clinical practice
Although VOCs profiling is a potential clinical tool, con-
siderable work needs to be done before it can be applied
into clinical practice. An important step that needs to be
taken is extensive validation of the current available VOCs
profiles. Next to (external) validation, standardization in
collecting and analyzing VOCs is necessary to enhance
inter-laboratory comparability. Due to the heterogeneity
of the included studies (in study design, sampling and ana-
lytical techniques) a variety of results is reported, making
it difficult to draw firm conclusions or to calculate an al-
gorithm for the most important compounds in the diverse
pulmonary diseases. In the standardization procedure, the
influence of potential confounders needs to be explored
before considering VOCs as a clinical tool [48]. As
described before, exhaled VOCs can arise from various
endogenous and exogenous sources. Consequently, nu-
merous environmental-, subject- and analytical factors can
influence the exhaled VOCs pattern (Table 5). For ex-
ample, air pollution, smoking, eating, drinking and medi-
cation use can considerably affect the composition of
exhaled VOCs [85]. Also the presence of bacteria can alter
exhaled VOCs patterns (hence breath analysis could be
used to identify bacterial infections and bacterial-induced
diseases). This suggests that these factors should be takenTable 5 Factors that can influence exhaled VOCs in
pulmonary diseases
Source Factor
Environment Ambient VOCs (e.g. by air pollution)
Temperature of environment
Humidity of inhaled and exhaled air
Season





Non-pulmonary chronic diseases (liver impairment,
diabetes, presence of bacteria)
Breathing pattern: e.g. exhaled flow, minute ventilation,
breath hold
Overall lifestyle and physical condition
Analysis Time and way of storage
Pre-concentration
Breath collection: mixed air or alveolar air
Collection method: e.g. tedlar bags, metal containers
Analytical method: e.g. eNose, GC-MSinto account when constructing a diagnostic tool on basis
of VOCs patterns. Moreover, potential confounders on
analytical level should be carefully studied. For example,
during the offline-procedure of exhaled VOCs collection,
Tedlar bags could release VOCs into the collected breath,
and storage onto Tenax columns can disturb the com-
position of the breath. As the pool of exhaled VOCs arises
from multiple endogenous and exogenous sources, the
analysis of background samples and standardization of the
analysis per technique is necessary. A list of recommenda-
tions for measurements composed by experts, as was
provided for markers in exhaled breath condensate, will
facilitate standardization [86]. Thirdly, more insight is
needed in the physiological meaning and biochemical
origin of endogenous formed VOCs. However, this might
be difficult since, as described before, the origin of VOCs
is blood-borne and therefore can be the result of widely
different biochemical pathways (so the previously
mentioned advantage of VOCs is a disadvantage as well).
Fourthly, more research is needed on the potential of
VOCs in differential diagnosis and monitoring purposes.
Besides these four major ‘missions’, others aspects of
VOCs assessment and analysis can be improved. Although
breath samples are easy to collect, the analysis of VOCs is
still quite cumbersome and time-consuming and requires
trained personnel. Moreover, further refinement of sam-
pling techniques, exploring advanced statistical techniques
on the multi-data of VOCs to build diagnostic and prog-
nostic models, and developing new tools that combine the
strengths of the eNose (cheap, time efficient), IMS (real-
time), and GC-MS (sensitive, compound identification)
will facilitate the introduction of VOCs into clinical
practice.
Conclusions
As the current available tools are not always fulfilling, there
is an increasing interest in non-invasive measurement of
exhaled VOCs to improve the diagnosis and management
of pulmonary diseases. Due to the complex pathophysi-
ology of most pulmonary diseases, current research mainly
focused on profiles of VOCs rather than on individual
compounds. Promising findings were reported on VOCs
profiles that were able to accurately diagnose and monitor
various pulmonary diseases. However, multiple constraints
including validation and standardization need to be
resolved before VOCs can be applied into clinical practice.
The rapid progress that is currently made in the field of
VOCs will facilitate the imminent introduction of VOCs
profiling as a non-invasive, additional tool to assist in
diagnosing and monitoring of pulmonary diseases.
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